User profiles for Michael Doukas

Doukas Michael

mosaiic GmbH
Verified email at mosaiic.com
Cited by 2241

[HTML][HTML] Simulation in manufacturing: Review and challenges

D Mourtzis, M Doukas, D Bernidaki - Procedia Cirp, 2014 - Elsevier
Simulation comprises an indispensable set of technological tools and methods for the
successful implementation of digital manufacturing, since it allows for the experimentation and …

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study

…, EW Steyerberg, JJB van Lanschot, M Doukas… - The Lancet …, 2018 - thelancet.com
Background After neoadjuvant chemoradiotherapy for oesophageal cancer, roughly half of
the patients with squamous cell carcinoma and a quarter of those with adenocarcinoma have …

[HTML][HTML] Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial

…, JJ Boonstra, PPLO Coene, JWT Dekker, M Doukas… - Bmc Cancer, 2018 - Springer
Background Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard treatment
for locally advanced oesophageal cancer. With this treatment, 29% of patients have a …

Loss of LMOD1 impairs smooth muscle cytocontractility and causes megacystis microcolon intestinal hypoperistalsis syndrome in humans and mice

…, Y Han, V Nanda, Q Lyu, M Doukas… - Proceedings of the …, 2017 - National Acad Sciences
Megacystis microcolon intestinal hypoperistalsis syndrome (MMIHS) is a congenital visceral
myopathy characterized by severe dilation of the urinary bladder and defective intestinal …

[HTML][HTML] Design and planning of manufacturing networks for mass customisation and personalisation: challenges and outlook

D Mourtzis, M Doukas - Procedia Cirp, 2014 - Elsevier
Manufacturers and service providers are called to design, plan and operate globalized
manufacturing networks, addressing to challenges such as ever-decreasing lifecycles and …

[HTML][HTML] Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib

…, CEMT Beerens, M Suker, M Doukas… - Theranostics, 2016 - ncbi.nlm.nih.gov
Metastases expressing tumor-specific receptors can be targeted and treated by binding of
radiolabeled peptides (peptide receptor radionuclide therapy or PRRT). For example, patients …

Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions

…, MP Peppelenbosch, W Lesterhuis, M Doukas… - Gut, 2019 - gut.bmj.com
Objective International guidelines recommend endoscopic surveillance of premalignant
gastric lesions. However, the diagnostic yield and preventive effect require further study. We …

The evolution of manufacturing systems: From craftsmanship to the era of customisation

D Mourtzis, M Doukas - Handbook of research on design and …, 2014 - igi-global.com
The transition from local economies to the global competitive landscape and the current
fluctuating customer demands drives a never-ending transformation of manufacturing systems. …

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

…, EB Anderson, MA Halepota, MA Doukas… - Investigational new …, 2005 - Springer
GW572016 is a dual EGFR-ErbB2 inhibitor that has promise as an anticancer agent. Two
phase I studies were conducted to determine the safety, tolerability and pharmacokinetics of …

Degassing of CO2, SO2, and H2S associated with the 2009 eruption of Redoubt Volcano, Alaska

C Werner, PJ Kelly, M Doukas, T Lopez… - Journal of Volcanology …, 2013 - Elsevier
The 2009 eruption of Redoubt Volcano, Alaska was particularly well monitored for volcanic
gas emissions. We report 35 airborne measurements of CO 2 , SO 2 , and H 2 S emission …